Palmitoylethanolamide for Health & Longevity - Quick Reference Sheet

Palmitoylethanolamide for Health & Longevity

Created on 09/29/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Sonnet 5.5 – Audit

Palmitoylethanolamide is a naturally occurring, fat-derived substance made in the body, sold as oral supplements and skin products, and studied mainly for pain and other symptoms. Human research offers credible but inconsistent evidence of pain relief, small studies that repeatedly found lower eye pressure, and evidence of fewer respiratory illness episodes. Over short periods, side effects are generally infrequent. Slower aging or longer life is not established. (Full Review)

Protocol

Common oral research range
300–1,200 mg/day
Often divided twice daily for four to twelve weeks; doses across preparations are not directly comparable
Timing
Morning/evening dosing
No controlled evidence establishes an optimal time or meal condition
Lower-dose pain approach
300 or 600 mg/day
Two divided doses for eight weeks in knee arthritis; later results on the main planned outcome were mixed
Time to effect
Fewer respiratory illness episodes
12 weeks
Duration of the trial reporting fewer episodes
Greater jump performance during resistance training
8 weeks
Duration of the resistance-training trial; jump height was an additional planned measure, not the main goal
Pain relief and associated daily function
4–8 weeks, sometimes 12
Selected acute menstrual pain measures improve within hours; broad, immediate pain relief is not established

Benefits

Contraindications
  • Known hypersensitivity to PEA or an ingredient in the selected formulation
  • Pregnant or breastfeeding people outside a supervised research setting
Key Interactions
  • Prescription pain medicines (pregabalin, duloxetine)
  • Psychiatric medicines (citalopram, lithium, risperidone)
  • Nonprescription pain medicines (acetaminophen, ibuprofen, naproxen)
  • Supplement combinations (luteolin, polydatin, acetyl-L-carnitine)
  • Cannabidiol, cannabis, and sedating supplements (melatonin)
  • Rehabilitation and psychological therapy

Risk & Side Effects

  • High:
  • Medium: Smaller bench-press strength gains
  • Low: Gastrointestinal symptoms; Skin reactions; Reduced sleep quality and loss of taste; Palpitations and tachycardia; Blurred vision; Worsened muscle tightness
  • Speculative: Severe allergic reaction; Headache, drowsiness, dizziness, and other minor symptoms

Monitoring

Marker Target Why
Blood PEA No established target; symptoms and function are tracked instead Unsupported dosing targets are avoided
Kidney and liver laboratory tests No PEA-specific optimal range; individual baseline and the laboratory's reference intervals are tracked Contextual safety
Eye pressure, when treating glaucoma Individual ophthalmologist-defined target; change from baseline is tracked Measures the relevant endpoint
Inflammation markers No PEA response target; the underlying clinical condition is tracked instead Success judged by a laboratory value alone is avoided

Cadence: Tolerance at one to two weeks, symptoms at four weeks, and continued benefit at eight to twelve weeks; longer use can be reassessed every three to six months. An observational framework, not a validated PEA monitoring schedule.

Qualitative Assessment

  • Symptoms: Pain and daily function are tracked, with strength compared consistently during resistance training.
  • Sleep and cognition: Sleep, alertness, and everyday performance are recorded.
  • Tolerance: Digestive, skin, visual, neurological, appetite, mouth/throat, and heartbeat symptoms are recorded.